Jobs entrusts a NYT columnist with the truth about his health, even before he tells Apple shareholders
An Apple (AAPL) spokeswoman lied recently when she said Steve Jobs' haggard look lately was due to a “common bug,” a remarkable piece in the New York Times this weekend strongly suggests.
Context & Ripple Effects
Questions about Jobs’s health had already become a market issue: reports of concern over Apple’s chief linked the uncertainty to pressure on Apple’s share price. The New York Times reporting adds a governance dimension, because Jobs was quoted discussing Apple’s culture of secrecy while health details were reportedly not being shared uniformly.
Apple’s consumer launches and developer updates continued alongside the controversy, making the issue less about day-to-day product activity than about whether investors receive material information consistently.
First-order effects
- Apple shareholders face a sharper disclosure and credibility question after reports that Jobs discussed his condition with a New York Times columnist before communicating it to them; the underlying account remains unconfirmed.
- Apple’s spokeswoman is placed under greater scrutiny because the reported explanation for Jobs’s appearance conflicts with the account attributed to the Times coverage.
Second-order effects
- AAPL trading is more exposed to leadership-health reporting when uncertainty around Jobs has already been associated with share-price pressure.
- The New York Times gains leverage over Apple’s narrative by publishing Jobs’s comments on secrecy, shifting investor attention from product execution to management communication.
Third-order effects
- The episode highlights how a company closely identified with one executive can turn private health information into a corporate-governance issue when investors view that executive as material to value.
- If Apple maintains a selective communication posture, market-moving reporting may increasingly originate with outside journalists rather than formal shareholder channels.
The trend: Apple’s leadership-health controversy is part of a broader tension between executive privacy, corporate secrecy, and investors’ demand for consistent disclosure when a founder is central to company value.